期刊文献+

血浆凝血酶激活的纤溶抑制物、视黄醇结合蛋白与2型糖尿病血管并发症的关系 被引量:2

下载PDF
导出
摘要 目的:通过分析凝血酶激活的纤溶抑制物(TAFI)在2型糖尿患者纤溶作用低下机制中所起的作用,它与2型糖尿病患者的血管内皮损伤、凝血系统和纤溶系统的关系,及视黄醇结合蛋白(RBP)与2型糖尿病肾病变及视网膜病变的关系,来评价TAFI、RBP在2型糖尿病患者并发血管病变的作用,旨在对2型糖尿病患者血管并发症的发病机制作进一步的探讨,从而为2型糖尿病患者血管并发症的早期干预及临床治疗提供新的理论依据。方法:血浆TAFI水平采用酶联免疫吸附试验(ELISA)法测定,纤维蛋白原(FIB)采用凝血酶法测定,UAER采用化学发光免疫方法测定,RBP采用免疫比浊法测定,采用SSPS 16.0系统软件对所获得的数据进行统计分析,计量资料以均数±标准差表示,差异显著性用单因素方差分析(One-wayANOVA)、LSD检验、t检验,血浆TAFI、FIB、RBP、UAER之间的关系通过Pearson相关系数检验。结果:与正常对照组比较,2型糖尿病无并发症组血浆TAFI、FIB、RBP水平升高,差异有显著性(p<0.05);而2型糖尿病血管并发症组血浆TAFI、FIB、RBP水平升高更显著,差异及显著(p<0.001)。同时,2型糖尿病微量白蛋白尿症患者血浆TAFI与UAER显著相关(p<0.001)。结论:2型糖尿病血管并发症的发生与血浆TAFI及RBP水平的升高有关。
出处 《牡丹江医学院学报》 2011年第4期44-46,共3页 Journal of Mudanjiang Medical University
  • 相关文献

参考文献8

  • 1Hendriks D, Seharpe S, van Sande M, et al. A labile enzyme in fresh human serum interferes with the assay of earboxypeptidase N [ J ]. Clin Chem, 1989,35 : 177.
  • 2Hori Y Gabazza EC ,Yano Y,et al. Insulin resistance is associated with increased cireulating level of thrombin activatable fibrinolysis inhibitor in type 2 diabetic patients [ J ]. J Clin Endocrinol Metab, 2002,87(2) :660 -665.
  • 3Klement P,Liao P,Bajzar L. A novel approach to arterial thrombolvsis[J] . Blood, 1999.94:2735.2743.
  • 4Yang Q, Graham TE, Medy N, et al. Serum retinol binding protein 4 contributes to insulin ~sistance in obesity and type 2 diebetes. Naturo,2005,436:356 - 362.
  • 5Laurent O . Mosnier, Paula Buijtenhuijs, et al. Identification of thrombin activatable fibfinolysis inhibitor( TAFI )in human plateletso Blood.2003.101 : 12.
  • 6彭彦孟(综述),彭家和(综述),周度金(综述),陈健(审校).视黄醇结合蛋白的研究进展[J].国际检验医学杂志,2007,28(8):736-737. 被引量:14
  • 7李琦,张雯,张学东.增殖性糖尿病视网膜病变伴重度黄斑水肿玻璃体蛋白质组学初步研究[J].重庆医科大学学报,2010,35(7):1043-1047. 被引量:2
  • 8Chew E Y, Klein M L. Assooeiation of elevated serum lipid levels with retinal hard exodate in diabetic retinopathy [ J ]. Early Treatment Diabetic Retinophy Study (ETDRS) report 22 Arch Ophthal- mo1,1996,114:1079 - 1084.

二级参考文献32

  • 1林维平,李思光,徐琪寿.视黄醇结合蛋白的分子机制及临床应用[J].军事医学科学院院刊,2005,29(5):492-495. 被引量:24
  • 2Liu S Q.Expressional differents in retinal protein between normal rats[J].World J Gastroenterol,2007,13(14):2118-2124.
  • 3Gerner C,Frohwein U,Gotzmann J,et al.The Fas induced apoptosis analyzed by high throughput proteome analysis[J].J Biol Chem,2000,275 (50):39018-39026.
  • 4Blom M L,Green W R,Schachat A P,et al.Diabetic retinopathy:a review[J].Del Med J,1994,66(7):379-388.
  • 5Patel A,Hibberd M L,Millward B A,et al.Chromosome Tq35 and diabetic microvascular eomplioation[J].J Diabetes Complications,1996,10 (2):61.
  • 6Kraft H G,Sandholzer C,Menzel H J,et al.Apolipoprotein (a) particle density and correntration in plasma[J].Arterioscler Thromb,Vasc Biol,1992,12(3):302-306.
  • 7Arcaro G,Zenere B M,Saggiani F,et al.ACE inhibitors improve endothelial function in type 1 diabetic patients with normal arterial pressure and microalbuminuria[J].Diabetes Care,1999,22(9):1536-1542.
  • 8Yang Q,Graham T E,Mody N,et al.Serum retinol binding protein 4 contributes to insulin resistance in obesity and tye 2 diabetes[J].Nature,2005,436(7049):356-362.
  • 9Toyofumi N,Reiko K,Tsunchiko I,et al.Catalogue of soluble proteins in the human vitreous humor:comparison between diabetic retinopathy and macular hole[J].Chromatography B,2002,776:89-100.
  • 10Meigs J B,Panhuysen C I,Myers R H,et al.A genome-wide scan for loci linked to plasma levels of glucose and HbAlc in a community-based sample of Caucasian pedigrees:The framitgsham off spring study[J].Diabetes,2002,51(3):833-840.

共引文献14

同被引文献10

  • 1Theuma P, Fonseca VA. Novel cardiovascular risk factors and macrovascular and microvascular complications of diabetes. Curr Drug Tar- gets,2003,4(6) :477-486.
  • 2Festa A, Agostino R,Tracy RP, et al. Elevated levels of acute 2 phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes. Diabetes,2002,51 (4) : 1131-1137.
  • 3Silha JV, Nyomba B LG, Lesliew D, et al. Ethnicity, insulin resist- ance, and inflammatory adipokines in women at high and low risk for vascular disease. Diabetes Care,2007,3 (2) : 286-291.
  • 4Bajzar L,Manuel R,Nesheim ME. Purification and characterization of TAFI,a thrombin activatable fibrinolysis inhibitor. J Bio Chem, 1995; 270 : 14477-14484.6.
  • 5Silveira A, ScbaiTernan K, Goosens F, et alPlasma Procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost ,2000,84 ( 3 ) :64-368.
  • 6Klement P,Liao P,Bajzar L. A novel approach to arterial thrombolys- is. Blood, 1999,94 ( 8 ) :2735-2743.
  • 7Hori Y, Gabazza EC, Yano, et al. Insulin resistance is associated with in- creased circulating level of thrombin activatable fibrinolysis inhibitor in type 2 diabetic patients. K Clin Endocrinol Metab ,2002,87(2) :660:65.
  • 8贾浩,张小白,宋晓峰.人类胞内蛋白半衰期与其亚细胞定位的相关性研究[J].计算机与应用化学,2011,28(4):411-414. 被引量:69
  • 9王胜江,徐成伟.慢性肝病患者血浆中凝血酶激活的纤溶抑制物(TAFI)水平与慢性肝损伤的相关性[J].山东大学学报(医学版),2012,50(4):83-86. 被引量:4
  • 10杨阳,张雪莲,张万锋,李文霞,李文新,蔡春波,路畅,高鹏飞,郭晓红,李步高,曹果清.猪C1QTNF3基因可变剪接体的鉴定及介导miR-101调控成脂分化的研究[J].畜牧兽医学报,2021,52(11):3042-3052. 被引量:1

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部